131 related articles for article (PubMed ID: 15345497)
1. Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis.
Wolf J; Stranzl T; Filipits M; Pohl G; Pirker R; Leeb B; Smolen JS
Ann Rheum Dis; 2005 Apr; 64(4):564-8. PubMed ID: 15345497
[TBL] [Abstract][Full Text] [Related]
2. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study.
Dervieux T; Furst D; Lein DO; Capps R; Smith K; Caldwell J; Kremer J
Ann Rheum Dis; 2005 Aug; 64(8):1180-5. PubMed ID: 15677700
[TBL] [Abstract][Full Text] [Related]
4. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis.
Dervieux T; Furst D; Lein DO; Capps R; Smith K; Walsh M; Kremer J
Arthritis Rheum; 2004 Sep; 50(9):2766-74. PubMed ID: 15457444
[TBL] [Abstract][Full Text] [Related]
5. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis.
Jansen G; van der Heijden J; Oerlemans R; Lems WF; Ifergan I; Scheper RJ; Assaraf YG; Dijkmans BA
Arthritis Rheum; 2004 Jul; 50(7):2130-9. PubMed ID: 15248210
[TBL] [Abstract][Full Text] [Related]
6. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone.
O'Dell JR; Elliott JR; Mallek JA; Mikuls TR; Weaver CA; Glickstein S; Blakely KM; Hausch R; Leff RD
Arthritis Rheum; 2006 Feb; 54(2):621-7. PubMed ID: 16447240
[TBL] [Abstract][Full Text] [Related]
7. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
8. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
9. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis.
Visvanathan S; Marini JC; Smolen JS; Clair EW; Pritchard C; Shergy W; Pendley C; Baker D; Bala M; Gathany T; Han J; Wagner C
J Rheumatol; 2007 Jul; 34(7):1465-74. PubMed ID: 17552048
[TBL] [Abstract][Full Text] [Related]
10. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
[TBL] [Abstract][Full Text] [Related]
11. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
[TBL] [Abstract][Full Text] [Related]
12. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis.
Tsujimura S; Saito K; Nawata M; Nakayamada S; Tanaka Y
Ann Rheum Dis; 2008 Mar; 67(3):380-8. PubMed ID: 17660216
[TBL] [Abstract][Full Text] [Related]
13. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years.
Strand V; Balbir-Gurman A; Pavelka K; Emery P; Li N; Yin M; Lehane PB; Agarwal S
Rheumatology (Oxford); 2006 Dec; 45(12):1505-13. PubMed ID: 17062648
[TBL] [Abstract][Full Text] [Related]
14. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
[TBL] [Abstract][Full Text] [Related]
15. Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug.
Hider SL; Owen A; Hartkoorn R; Khoo S; Back D; Silman AJ; Bruce IN
Ann Rheum Dis; 2006 Oct; 65(10):1390-3. PubMed ID: 16504991
[TBL] [Abstract][Full Text] [Related]
16. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
[TBL] [Abstract][Full Text] [Related]
17. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis.
Berkun Y; Abou Atta I; Rubinow A; Orbach H; Levartovsky D; Aamar S; Arbel O; Dresner-Pollak R; Friedman G; Ben-Yehuda A
J Rheumatol; 2007 Aug; 34(8):1664-9. PubMed ID: 17611986
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
Ogrendik M
Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of methotrexate resistance in osteosarcoma.
Guo W; Healey JH; Meyers PA; Ladanyi M; Huvos AG; Bertino JR; Gorlick R
Clin Cancer Res; 1999 Mar; 5(3):621-7. PubMed ID: 10100715
[TBL] [Abstract][Full Text] [Related]
20. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]